Compare WIA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | QNCX |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.5M | 167.0M |
| IPO Year | N/A | 2019 |
| Metric | WIA | QNCX |
|---|---|---|
| Price | $7.99 | $0.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 56.1K | ★ 16.2M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.97 | $0.08 |
| 52 Week High | $8.54 | $4.55 |
| Indicator | WIA | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 26.50 | 29.94 |
| Support Level | N/A | $0.09 |
| Resistance Level | $8.31 | $0.98 |
| Average True Range (ATR) | 0.06 | 0.01 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 17.02 | 66.12 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.